02:38am Sunday 22 October 2017

Selecting the Right Tool For the Job: Ethics Surrounding Drug Trials During Deadly Infectious Disease Outbreaks

However, in the case of a deadly, rapidly spreading, infectious disease with no known cure, such as Ebola, ethical considerations demand that reliance only on RCTs be reexamined, according to a new study online in the American Journal of Bioethics.

Authors Bruce Levin, PhD, professor of Biostatistics at Columbia University’s Mailman School of Public Health and Arthur Caplan, PhD and  Carolyn Plunkett of the Division of Medical Ethics giin the Department of Population Health at  NYU Langone Medical Center, note that “If the goal of conducting trials in epidemic ravaged West  Africa is to rapidly find an intervention that cures the infected and blunts the epidemic, then Randomized Clinical Trial designs are not the only or even the best choice. The World Health Organization, Doctors without Borders, and other partners who coordinate trials on experimental agents agree.  There are practical reasons why placebo or Standard of Care (SOC)-controlled trials are difficult if not impossible to undertake.”

“Local governments and communities will not accept placebo controlled trials in the face of a deadly epidemic especially when there is reason to believe that drugs or other interventions are relatively safe.  Nor should they when other trial designs are more appropriate,” said Dr. Caplan.
 
The authors further note that there are competing ethical concerns when it comes to designing any clinical research study – and clinical trials of possible treatments for Ebola virus are no exception.  If anything, they conclude, competing ethical concerns are exacerbated in trying to find answers to a deadly, rapidly spreading, infectious disease. The primary goal of current research is to identify experimental therapies that can cure Ebola or cure it with reasonable probability in infected individuals.
 
“Pursuit of that goal must be methodologically sound, practical and consistent with prevailing norms governing human subjects research,” the authors write. “Some maintain that only randomized controlled trials (RCTs) with a placebo or standard-of-care arm can meet these conditions. We maintain that there are alternative trial designs that can do so as well and that sometimes these are preferable to RCTs.” 

In their article, the authors further point out that the guiding methodologic question of clinical trials  in an epidemic that has spread out of control is not to test a “null hypothesis” that nothing works in carefully controlled circumstances but, rather, to assess among potentially promising agents, some of which have proven safety records, which stands the best chance of working using – a randomized selection” (RS) trial, which has the primary objective of identifying the “best candidate” for the treatment of Ebola or other deadly diseases among competing options. They also write that it is particularly important to recognize that testing against the null hypothesis is neither appropriate nor necessary at this point in an out-of-control lethal epidemic. “Instituting alternative clinical trial designs can provide useful information for the elimination or selection of prospective therapies. And that is what morally we owe those who are dying or at grave risk in environments where they have no other realistic means of survival.”

“The conventional ways of designing randomized clinical treatment trials in the midst of truly horrific epidemics like the current Ebola Virus Disease outbreak are inadequate,” stated Dr. Levin. “Researchers have an obligation to do better.  We have proposed a design—the randomized selection trial—which addresses the moral responsibility to find promising treatments quickly with a design that respects the needs of those whose lives are at greatest risk.”

The article provoked a good deal of accompanying commentary, including from leading figures at the FDA and NIH.  The authors respond to these comments hoping that some consensus can be reached about how best to respond in emergencies with new drugs and agents before the next deadly pandemic.

###

About Columbia University’s Mailman School of Public Health

Founded in 1922, Columbia University’s Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master’s and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu

About NYU Langone Medical Center

NYU Langone Medical Center, a world-class, patient-centered, integrated academic medical center, is one of the nation’s premier centers for excellence in clinical care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals—Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, the Medical Center’s dedicated inpatient orthopaedic hospital; and Hassenfeld Children’s Hospital, a comprehensive pediatric hospital supporting a full array of children’s health services across the Medical Center—plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The Medical Center’s tri-fold mission to serve, teach, and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education, and research.


Share on:
or:

Health news